Literature DB >> 23407231

Sarcoidosis-associated pulmonary hypertension in patients with near-normal lung function.

N Maimon1, L Salz, Y Shershevsky, A Matveychuk, A Guber, D Shitrit.   

Abstract

SETTING: Tertiary care medical centre in Israel.
BACKGROUND: Pulmonary hypertension (PH) is a predictor of poor outcome in patients with sarcoidosis. Early diagnosis may improve outcome.
OBJECTIVE: To determine factors that might contribute to the early diagnosis of PH in sarcoidosis patients with near normal lung function tests.
DESIGN: Retrospective patient review.
METHODS: Data from 127 patients with sarcoidosis and near normal lung function tests (forced vital capacity > 70%, forced expiratory volume in 1 second > 70% and diffusion capacity of carbon monoxide [D(LCO)] > 60%), who underwent high resolution computed tomography (HRCT) scan, the 6-minute walk distance (6MWD) test and echocardiogram were analysed. Demographic, clinical and HRCT findings were compared between patients with and those without PH.
RESULTS: Thirty-six patients (28.3%) had PH. Patients with PH tended to have lower D(LCO) (68% ± 8 vs. 75% ± 17, P = 0.038), 6MWD (308 m ± 106 vs. 486 m ± 99, P = 0.009) and exercise saturation (91 ± 4 vs. 95 ± 3, P = 0.0001) compared to those without PH. HRCT patterns in PH showed higher frequencies of interstitial thickening (P = 0.004), ground glass appearance (P = 0.01) and fibrosis (P = 0.032). In logistic regression, only 6MWD was predictive of PH (P = 0.005, 95%CI 0.970-0.995).
CONCLUSION: Physiological and radiographic characteristics appeared to differentiate patients with PH from those without. Physicians should be aware of PH in patients with sarcoidosis, even in those with near normal lung function.

Entities:  

Mesh:

Year:  2013        PMID: 23407231     DOI: 10.5588/ijtld.12.0428

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

1.  Prostacyclin and oral vasodilator therapy in sarcoidosis-associated pulmonary hypertension: a retrospective case series.

Authors:  Catherine A Bonham; Justin M Oldham; Mardi Gomberg-Maitland; Rekha Vij
Journal:  Chest       Date:  2015-10       Impact factor: 9.410

2.  Racial difference in sarcoidosis mortality in the United States.

Authors:  Mehdi Mirsaeidi; Roberto F Machado; Dean Schraufnagel; Nadera J Sweiss; Robert P Baughman
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

Review 3.  From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis.

Authors:  Catherine A Bonham; Mary E Strek; Karen C Patterson
Journal:  Curr Opin Pulm Med       Date:  2016-09       Impact factor: 3.155

4.  Sarcoidosis-associated Pulmonary Hypertension: Pathophysiology, Diagnosis, and Treatment.

Authors:  Heng Duong; Catherine A Bonham
Journal:  Clin Pulm Med       Date:  2018-03

5.  Defining prognosis in sarcoidosis.

Authors:  Mariana Carneiro Lopes; Thaís Porto Amadeu; Marcelo Ribeiro-Alves; Claudia Henrique da Costa; Bruno Rangel Antunes Silva; Luciana Silva Rodrigues; Elisabeth Jauhar Cardoso Bessa; Leonardo Palermo Bruno; Agnaldo José Lopes; Rogerio Rufino
Journal:  Medicine (Baltimore)       Date:  2020-11-25       Impact factor: 1.889

6.  Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT™) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): a qualitative interview study.

Authors:  Brooke M Currie; Evan W Davies; Amélie Beaudet; Larissa Stassek; Leah Kleinman; Robert P Baughman
Journal:  BMC Pulm Med       Date:  2021-11-12       Impact factor: 3.317

Review 7.  Pulmonary hypertension complicating pulmonary sarcoidosis.

Authors:  M P Huitema; J C Grutters; B J W M Rensing; H J Reesink; M C Post
Journal:  Neth Heart J       Date:  2016-06       Impact factor: 2.380

8.  Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Elliott D Crouser; Lisa A Maier; Kevin C Wilson; Catherine A Bonham; Adam S Morgenthau; Karen C Patterson; Eric Abston; Richard C Bernstein; Ron Blankstein; Edward S Chen; Daniel A Culver; Wonder Drake; Marjolein Drent; Alicia K Gerke; Michael Ghobrial; Praveen Govender; Nabeel Hamzeh; W Ennis James; Marc A Judson; Liz Kellermeyer; Shandra Knight; Laura L Koth; Venerino Poletti; Subha V Raman; Melissa H Tukey; Gloria E Westney; Robert P Baughman
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

9.  Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Shijie Zhang; Xiang Tong; Tianli Zhang; Dongguang Wang; Sitong Liu; Lian Wang; Hong Fan
Journal:  Front Cardiovasc Med       Date:  2022-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.